-
Opinion: This tiny biotech company takes the real ice bucket challenge
Financial writer, Michael Brush, looks ahead of the $100 million-plus raised in the ALSA Ice Bucket Challenge to the potential of biotech treatments for ALS. Neuralstem’s recently completed NSI-566/ALS Phase II and upcoming Phase II/III trials are the focus of the opinion piece. Principal Investigator, Eva Feldman, MD, PhD, notes that she hopes “the ice bucket money goes to fast-tracking new therapies,” and Neuralstem’s President and CEO, Richard Garr, projects that, “We could be as close as two years away from commercialization.”